Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Article below is quoted in todays 8K.

The following MOA in the article are suggested by IPIX in today's announcement and previous publications.

1. Envelope protein (E) (SARS-CoV-2; COVID-19 virus)Envelope protein is a component of the viral envelope of COVID-19 that plays a central role in virus morphogenesis and assembly via its interactions with other viral proteins.Agents that are envelope protein-directed immunity induc-ers may be effective in developing a vaccine against SARS-CoV-2 (12-14).

2.Interleukin-6 receptor subunit a (IL-6RA)IL-6RA is the a chain of the IL-6 receptor complex (IL-6R). IL-6R is a class I cytokine receptor for IL-6. Association with the IL6ST subunit is required for a full functional receptor. The complex is involved in immune response regulation, acute-phase reaction and hematopoiesis. When SARS-CoV-2 infects the upper and lower respiratory tract, the results can be mild or highly acute respiratory syndrome with conse-quent release of proinflammatory cytokines, including IL-6. Suppression of inflammation in inflammatory diseases can be achieved by inhibiting IL-6 activity. Anti-IL-6RA agents would render IL-6R inactive and attenuate pulmonary inflammation in patients with COVID-19 (18-20).

3. Membrane glycoprotein (M) (SARS-CoV-2; COVID-19)Membrane glycoprotein M is a component of the viral enve-lope of SARS-CoV-2 that plays a central role in virus mor-phogenesis and assembly via its interactions with other viral proteins. Agents which are membrane glycoprotein-directed immunity inducers may be effective in the preven-tion of COVID-19 (12-14).

4.Surface glycoprotein (S) (SARS-CoV-2; COVID-19)Surface glycoprotein attaches the virion to the cell mem-brane by interacting with human ACE-2 (angiotensin-converting enzyme 2) and CLEC4M/DC-SIGNR (C-type lectin domain family 4 member M) and initiates the infection. Binding to the receptor and internalization of the virus into the endosomes of the host cell probably induces confor-mational changes in the S glycoprotein. Targeting of this molecule by nucleocapsid-directed immunity inducers may be effective in the prevention and treatment of SARS-CoV-2

5.Tumor necrosis factor ligand superfamily member 6 (FASLG; FAS ligand; FasL) and tumor necrosis factor receptor type 6 (FASL receptor; Fas)FAS ligand (FasL) is a type-II transmembrane, homotri-meric protein that belongs to the tumor necrosis factor (TNF) family. It is a ligand of Fas, a member of the TNF receptor family that is involved in the induction of cell death through caspase-mediated signaling. FasL/Fas interactions play an important role in the regulation of the immune system and the progression of cancer. Fas signaling also appears to regulate endothelial func-tion and neutrophil lifespan. Studies have shown that caspase-dependent FasL-mediated apoptotic pathways play a central role in SARS-CoV-induced apoptosis which facilitates viral replication. Thus, inhibition FasL/Fas interaction may be effective in the treatment of SARS-CoV-2 (22, 31-34).

https://clarivate.com/wp-content/uploads/2020/04/16015-0803f-DOF-0049-2020.R01_AP.pdf